EnteroMedics (ETRM) Receives Notice of Intention to Grant a European Patent Related to vBloc Therapy
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
EnteroMedics Inc. (Nasdaq: ETRM) announced that the European Patent Office has issued a Notice of Intention to Grant a European Patent covering safety features of the Company's vBloc® Neurometabolic Therapy System. The intention to grant the European patent follows the granting of U.S. patent No. 9,393,420 on July 19, 2016, which covers safety features for an implantable neuroregulator with a rechargeable battery. EnteroMedics has been granted three U.S. patents to date in 2016. The Company holds more than 70 patents on its technology worldwide.
"Receipt of the Notice of Intention to Grant a European Patent underscores the strength and robust nature of our intellectual property portfolio, and reaffirms EnteroMedics' dominant presence within the neuromodulation device industry in the areas of obesity and gastrointestinal disorders," said Dan Gladney, President and CEO, EnteroMedics Inc. "As we continue to commercialize and seek broad reimbursement coverage for vBloc Therapy in the United States of America, we look forward to the opportunity to offer our technology in international markets."
vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally-invasive procedure. The device helps patients feel full and in turn is a key tool in achieving clinically meaningful weight loss. When patients feel the sensation of fullness, they are able to control their appetite, and lose weight without the major lifestyle implications of traditional bariatric surgeries. Unlike traditional surgical weight loss, vBloc Therapy is a long-term solution, which if necessary, can be safely disabled or removed without leaving permanent damage to patient anatomy.
vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a Body Mass Index (BMI) of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Depomed (DEPO) Announces Favorable Ruling on NUCYNTA Providing Market Exclusivity Until December 2025
- Amyris (AMRS) Enters New Funding Arrangement, Expanded Nutraceutical Collaboration
- Calamp Corp. (CAMP) Selected as CalAmp (CAMP) Master Value-Added Distributor
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!